Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Core Viewpoint - Immuneering has appointed Dr. Igor Matushansky as Chief Medical Officer to lead clinical activities and oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, with plans for a pivotal Phase 3 trial in the future [1][2] Company Overview - Immuneering is a clinical-stage oncology company focused on developing and commercializing therapies that are more effective and better tolerated for cancer patients [3] - The lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK aimed at improving tolerability and expanding indications for RAS-driven tumors, including pancreatic cancer [3] Clinical Development - The ongoing Phase 2a trial of IMM-1-104 is designed to provide first-line pancreatic cancer patients with a new treatment option that is more effective and better tolerated than current standard care [2] - The company plans to present updated data from the Phase 2a trial in Q2 2025 [1] Leadership Experience - Dr. Matushansky brings extensive oncology drug development experience, having previously served as Chief Medical Officer at Sail Biomedicines and held senior roles at Ipsen Pharmaceuticals and Hookipa Pharma [2] - His background includes overseeing the completion of NAPOLI-3, which led to the approval of NALIRIFOX for first-line pancreatic cancer [2]